Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology have significantly reduced complication rates (such as that of restenosis). However, there are gaps where a high number of undesirable events prevail, such as small vessel disease (SVD), for which, in previous studies up, the rate of<a href="https://solaci.org/en/2023/04/28/piccoleto-ii-drug-coated-balloons-in-small-vessels/" title="Read more" >...</a>
Using drug-eluting balloons in patients with ST-segment elevation acute coronary syndrome. The benefits of early reperfusion in ST-segment elevation acute coronary syndromes (STEACS) have not been discussed; compared with fibrinolysis, primary percutaneous coronary intervention (pPCI) has shown benefits in terms of mortality. Despite the constant advancements in stent technology and design, these devices are not<a href="https://solaci.org/en/2023/04/18/drug-eluting-balloon-in-steacs-leaving-no-trace-is-beneficial/" title="Read more" >...</a>
Score to predict the risk of repeat PCI in DES restenosis. With the use of drug eluting stents (DES) instent restenosis (ISR) has seen a significant reduction vs. bare metal stents (BMS) restenosis. The main cause of DES failure is ISR. This entity is difficult to manage because of its high recurrence and reintervention risk.<a href="https://solaci.org/en/2023/04/12/isar-score-can-we-predict-the-need-for-repeat-pci-in-des-restenosis/" title="Read more" >...</a>
New unibody endologix endografts for the endovascular repair of abdominal aortic aneurysm 3-4-year safety followup At present, we have seen endovascular intervention of abdominal aortic aneurysm (EVAR) increase over surgical repair. However, the procedure is not free from complications, endoleak being the most frequent. Indeed, according to different series, it has a 20-25% incidence in AAA. Most<a href="https://solaci.org/en/2023/03/30/safe-aaa-are-the-new-endologix-devices-for-abdominal-aortic-aneurysm-safe-3-year-followup/" title="Read more" >...</a>
Below, we share February’s most read scientific abstracts in interventional cardiology at solaci.org. Can Drug Coated Balloon Be a Valid Option for Small Vessels? One of the challenges of percutaneous coronary interventions (PCI) are <2.5 mm vessels, since complications and restenosis complications rate are higher than with >3.0 mm vessels. Is Using Drug-Eluting Balloons and<a href="https://solaci.org/en/2023/03/22/the-most-read-scientific-articles-in-interventional-cardiology-in-february-on-our-website/" title="Read more" >...</a>
Left atrial appendix closure (LAAC) has become a frequent intervention for stroke prevention in patients with atrial fibrillation (AF) that make poor candidates for anticoagulation. However, it presents a complication with negative impact on procedural outcomes which is peridevice leak. To reduce these complications, we use intra-procedural imaging, the transesophageal echocardiogram (TEE) being the most<a href="https://solaci.org/en/2023/03/02/intracardiac-echocardiography-to-guide-watchman-left-atrial-appendix-closure-safe-and-effective/" title="Read more" >...</a>
Prospective registry of PTE patients who underwent FlowTriever, with 6 months of follow-up. The clinical relevance of interventional treatment in pulmonary thromboembolism (PTE) is often discussed, and no clinical studies have demonstrated a decrease in “hard” outcomes such as mortality. However, in recent years the use of catheter-directed therapies has increased, either through its main indication,<a href="https://solaci.org/en/2023/03/02/flash-registry-mechanical-thrombectomy-with-flowtriever/" title="Read more" >...</a>
Recent studies have shown that a drug coated balloons (DCB) based approach resulted non inferior when compared against drug eluting stents (DES) only approach in patients with instent restenosis and de novo lesions in small vessel disease. So far, two international consensuses have reported the use of DCB is feasible and safe to treat native<a href="https://solaci.org/en/2023/02/22/should-we-use-drug-coated-balloons-in-patients-with-multivessel-disease/" title="Read more" >...</a>
Recent studies have shown that drug-eluting stents with biodegradable polymer and ultrathin struts are safe and effective, including low rates of stent thrombosis. This is why researchers conducted the BIODEGRADE (Biomatrix and Orsiro Drug-Eluting Stents in Angiographic Result in Patients With Coronary Artery Disease) study, which showed the non-inferiority at 18 months of ultrathin biodegradable polymer<a href="https://solaci.org/en/2023/02/16/biodegrade-does-stent-design-affect-long-term-clinical-results/" title="Read more" >...</a>
Monotherapy in patients with complex angioplasty: meta-analysis of 5 randomized studies. Even though prolonged dual antiplatelet therapy (DAPT) might reduce the risk of important ischemic complications, this reduction will come at the expense of a significant increase of bleeding risk, which makes us reassess the cost benefit ratio of this decision. This is also why<a href="https://solaci.org/en/2023/02/10/monotherapy-with-p2y12-in-complex-interventions-less-and-less-risky/" title="Read more" >...</a>